Veracyte to Acquire HalioDx, Solidifying Global Leadership in Cancer Diagnostics     Learn More
Veracyte to Acquire HalioDx, Solidifying Global Leadership in Cancer Diagnostics     Learn More
Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
First study demonstrating Decipher Prostate test can inform treatment decisions in nmCRPC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data demonstrating the prognostic utility of the company’s Decipher ® Prostate genomic
View HTML
Toggle Summary Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder
First Molecular Subtyping Test to Gain Medicare Coverage to Inform Treatment for Individuals With Bladder Cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 4, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Medicare Administrative Contractors Palmetto GBA, WPS and CGS
View HTML
Toggle Summary Veracyte to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 2, 2021-- Details of the Raymond James Human Health Innovation Conference have been corrected. The updated release reads: VERACYTE TO PRESENT AT UPCOMING INVESTOR CONFERENCES Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company,
View HTML
Toggle Summary Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth
Fueling growth by enabling IVD test development and manufacturing, deepening scientific capabilities and expanding cancer diagnostics scope to 8 of the 10 top cancers in the U.S. Investor conference call and webcast today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun.
View HTML
Toggle Summary Veracyte to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman, chief executive officer and incoming executive chairman, and Marc Stapley , incoming chief executive officer, are
View HTML
Toggle Summary Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples
Study findings to be presented June 4 at ASCO Annual Meeting SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2021-- Veracyte, Inc ., (Nasdaq: VCYT) announced today new data that show the company’s Afirma Xpression Atlas (XA) can identify clinically relevant gene fusions in thyroid nodule
View HTML
Toggle Summary Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier
- VANDAAM study findings confirm test predicts aggressive prostate cancer in African American men - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 25, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data from two studies that further demonstrate the Decipher ® Prostate Genomic
View HTML
Toggle Summary Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection
Company to hold webcast to discuss findings on Thursday, May 20 , at 10:00 a.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 19, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced pivotal clinical validation data showing that the company’s noninvasive nasal swab test can significantly
View HTML
Toggle Summary Veracyte to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 18, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman, chief executive officer and incoming executive chairman, and Marc Stapley , incoming chief executive officer, are
View HTML
Toggle Summary Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis
New findings presented at ATS 2021 Conference also suggest novel test can be successfully enabled on nCounter Analysis System to support international expansion SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced that data reinforcing the
View HTML